Literature DB >> 23737091

How do we define complete remission for acute myeloid leukemia in the current era? Results of an international survey.

Michael J Burke, Linda Burns, Michael A Linden, Bruce Lindgren, Michael R Verneris, Daniel Weisdorf, Celalettin Ustun.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23737091      PMCID： PMC3772519          DOI： 10.1002/ajh.23497

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  3 in total

1.  MRD in AML: time for redefinition of CR?

Authors:  Gert Ossenkoppele; Gerrit Jan Schuurhuis
Journal:  Blood       Date:  2013-03-21       Impact factor: 22.113

2.  Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.

Authors:  Eric Jourdan; Nicolas Boissel; Sylvie Chevret; Eric Delabesse; Aline Renneville; Pascale Cornillet; Odile Blanchet; Jean-Michel Cayuela; Christian Recher; Emmanuel Raffoux; Jacques Delaunay; Arnaud Pigneux; Claude-Eric Bulabois; Céline Berthon; Cécile Pautas; Norbert Vey; Bruno Lioure; Xavier Thomas; Isabelle Luquet; Christine Terré; Philippe Guardiola; Marie C Béné; Claude Preudhomme; Norbert Ifrah; Hervé Dombret
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

3.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

Authors:  Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.